Ascendis Pharma A/S (NASDAQ:ASND – Get Rating)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2022 earnings at ($9.07) EPS and FY2023 earnings at ($10.94) EPS.
A number of other analysts have also recently issued reports on ASND. Morgan Stanley lowered their target price on Ascendis Pharma A/S from $152.00 to $148.00 and set an “overweight” rating for the company in a research note on Thursday, August 11th. Wells Fargo & Company increased their target price on Ascendis Pharma A/S from $167.00 to $172.00 and gave the stock an “overweight” rating in a research note on Thursday. SVB Leerink lowered their target price on Ascendis Pharma A/S from $174.00 to $168.00 and set an “outperform” rating for the company in a research note on Thursday, August 11th. Oppenheimer lowered their target price on Ascendis Pharma A/S from $154.00 to $144.00 and set an “outperform” rating for the company in a research note on Thursday, August 11th. Finally, Berenberg Bank reissued a “buy” rating and set a $166.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus price target of $153.70.
Ascendis Pharma A/S Stock Performance
Ascendis Pharma A/S stock opened at $103.88 on Wednesday. The company has a current ratio of 9.66, a quick ratio of 8.78 and a debt-to-equity ratio of 0.82. Ascendis Pharma A/S has a 1 year low of $61.58 and a 1 year high of $172.65. The company has a market cap of $5.92 billion, a PE ratio of -13.17 and a beta of 0.66. The company’s 50-day moving average is $94.55 and its two-hundred day moving average is $96.67.
Institutional Investors Weigh In On Ascendis Pharma A/S
Several large investors have recently made changes to their positions in ASND. Goldman Sachs Group Inc. boosted its holdings in shares of Ascendis Pharma A/S by 3,024.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,754,458 shares of the biotechnology company’s stock valued at $205,903,000 after buying an additional 1,698,302 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Ascendis Pharma A/S by 14.6% during the 1st quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company’s stock valued at $547,552,000 after purchasing an additional 594,855 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Ascendis Pharma A/S by 6.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,165,375 shares of the biotechnology company’s stock valued at $480,173,000 after purchasing an additional 295,224 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Ascendis Pharma A/S during the 2nd quarter valued at $25,689,000. Finally, Capital International Investors acquired a new stake in Ascendis Pharma A/S during the 1st quarter valued at $28,894,000.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.
- Get a free copy of the StockNews.com research report on Ascendis Pharma A/S (ASND)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.